Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
ID: 351499Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $300K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/351499

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-017.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for the Early-Stage Development of Informatics Technologies for Cancer Research and Management, aimed at advancing innovative informatics tools that enhance data acquisition, management, and analysis in cancer research. The initiative focuses on developing tools that engage users and address various aspects of cancer research, including biology, treatment, early detection, and health disparities, with an emphasis on early-stage development. Approximately $2.25 million is available for 5-6 awards, with individual budgets capped at $300,000 per year for a maximum of three years. Applications are due by November 15, 2024, and interested parties can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-017.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-017-Full-Announcement.html
    RFA-CA-24-017.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Notice of Funding Opportunity (NOFO) seeking applications for the Early-Stage Development of Informatics Technologies for Cancer Research and Management. This funding aims to support the development of innovative informatics tools that enhance data acquisition, management, and analysis across various aspects of cancer research, including biology, treatment, early detection, and health disparities. The program focuses on early-stage tool development, emphasizing user engagement and feedback to ensure relevance and effectiveness in the cancer research community. Funding of approximately $2.25 million is available for 5-6 awards, with budgets capped at $300,000 per year over a maximum of three years. Eligible applicants include higher education institutions, nonprofits, and various governmental bodies. Applications are due by November 15, 2024, with a range of specific requirements outlined for submission and review processes to ensure adherence to NIH standards. Overall, this initiative supports the advancement of informatics technologies crucial for enhancing cancer research outcomes and collaboration among various stakeholders.
    Similar Opportunities
    Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Advanced Development of Informatics Technologies for Cancer Research and Management" (RFA-CA-24-018). This initiative aims to support cooperative agreements that focus on the enhancement of emerging informatics technologies to improve data acquisition, management, analysis, and dissemination across the cancer research continuum. The program is particularly significant as it seeks to advance technologies that have shown initial viability but require further development to achieve a broader impact in cancer research, addressing critical health disparities and improving patient outcomes. NIH anticipates funding approximately four awards totaling $3.6 million for fiscal year 2025, with individual budgets capped at $600,000 per year over a five-year period. Applications are due by November 15, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the development of innovative informatics methods and algorithms aimed at enhancing cancer research and management through the R21 exploratory/developmental research grant. This initiative seeks applications that propose novel approaches to improve data acquisition, analysis, visualization, and interpretation across various aspects of cancer research, including biology, treatment, diagnosis, and health disparities. The NIH plans to fund approximately five awards totaling $1,020,000, with individual project budgets not exceeding $275,000 for a two-year period. Interested applicants must submit their proposals by November 15, 2024, and can find additional information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) cooperative agreement. This funding opportunity aims to enhance the development and sustainment of informatics research resources that improve data acquisition, analysis, visualization, and interpretation across various cancer research domains, including biology, treatment, prevention, and health disparities. The initiative is crucial for maintaining and improving existing informatics tools that support cancer research, emphasizing the need for robust sustainability plans and community engagement. Approximately $1,130,000 in funding is available, with applications accepted starting May 11, 2024, and a final submission deadline of November 15, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This grant aims to support exploratory research projects focused on the early-stage development of innovative technologies that enhance molecular and cellular analysis capabilities in cancer research, with an emphasis on technical innovation and addressing cancer health disparities. The total funding available is approximately $4.2 million, with individual grants of up to $150,000 per year for a maximum of three years. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-008.html.
    Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" initiative, which is part of the Innovative Molecular Analysis Technologies (IMAT) Program. This funding opportunity aims to support exploratory research projects that address significant gaps in current cancer research methodologies, focusing on the development and validation of novel technologies that enhance the understanding and treatment of cancer, including early detection, screening, and addressing health disparities. Eligible applicants can request up to $300,000 annually for a project period not exceeding three years, with a total of approximately $4.3 million available for 10 anticipated awards in fiscal year 2025. Applications will be accepted starting March 1, 2024, with a submission deadline of October 2, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)" aimed at supporting exploratory research projects that develop innovative technologies to enhance the quality of biospecimens used in cancer research. The initiative focuses on addressing pre-analytical degradation of cancer-relevant biospecimens during collection, processing, and storage, with the goal of improving sample integrity and utility for downstream analyses. This funding is particularly significant for advancing research in cancer biology, early detection, and treatment, while also addressing health disparities. Grants of up to $150,000 are available, with applications opening on March 1, 2024, and a submission deadline of October 1, 2024. For more information, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-010.html.
    Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on developing and validating innovative technologies to enhance the quality of biospecimens used in cancer research, specifically addressing pre-analytical variations that can compromise sample integrity. The program is part of the Innovative Molecular Analysis Technologies (IMAT) initiative and seeks projects that demonstrate preliminary data supporting their feasibility, with a funding ceiling of $300,000 per year for up to three years. Applications are due by October 1, 2024, and interested applicants can find more information and guidance by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-011.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering exploratory grants (R21 Clinical Trial Optional) aimed at advancing cancer control research. This funding opportunity encourages innovative approaches to understanding cancer etiology, behavior modification, and screening techniques, focusing on the early stages of impactful research that can significantly enhance population-based cancer research. Grants will provide up to $275,000 over two years, with a maximum of $200,000 available in a single year, and applications are due by October 8, 2024. Interested applicants can find more information and contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)." This initiative invites revision applications from currently funded NCI R01 research projects, encouraging applicants to enhance their original research by integrating innovative technologies developed through the NCI Innovative Molecular Analysis Technologies (IMAT) program. The goal is to foster interdisciplinary collaboration and accelerate scientific discovery in cancer research. Interested applicants can apply for grants of up to $150,000 annually for a maximum of two years, with applications accepted starting March 1, 2024, and a submission deadline of October 1, 2024. For further details, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-012.html.